【摘要】 目的观察ABD活性因子对肺癌患者化疗后骨髓抑制情况的影响。方法选取44例接受化疗的肺癌患者,随机分为干预组、对照组,22例干预组患者口服ABD活性因子,22例治疗背景相同的对照组患者作常规化疗,比较两组患者骨髓抑制情况的差异。结果 43例患者按计划完成化疗,对照组1例患者因重度骨髓抑制终止化疗。干预组骨髓抑制情况显著改善(P<0. 05)。与对照组比较,干预组Ⅲ～Ⅳ级骨髓抑制率显著降低(P <0. 05),且白细胞、中性粒细胞、血小板抑制情况显著改善(P <0. 05,P <0. 05,P <0. 05)。与对照组比较,干预组(非小细胞肺癌:紫杉醇+顺铂,培美曲塞+顺铂)化疗药物导致的骨髓抑制情况明显改善(P <0. 05,P <0. 05,P <0. 05,P <0. 05)。结论 ABD活性因子可改善肺癌患者化疗后骨髓抑制情况,尤其降低Ⅲ～Ⅳ级骨髓抑制发生率,提升白细胞、中性粒细胞、血小板水平,同时降低铂类、紫杉醇类、抗代谢类化疗药物毒副作用。更多还原

【Abstract】 Objective To explore the effect of ABD bioactives on myelosuppression alleviation in lung cancer patients during chemotherapy.Methods 44 lung cancer patients who received chemotherapy were randomly divided into intervention group and control group.22 lung patients in intervention group received ABD Bioactives for adjuvant therapy.22 lung cancer patients were treated conventionally.The difference of myelosuppression was compared between the two groups.Results 43 patients completed chemotherapy as planned,and 1 patients of the control group terminated chemotherapy due to severe myelosuppression.Myelosuppression of intervention group was significantly alleviated(P <0.05).The incidence of myelosuppression of Ⅲ～Ⅳ was significantly lower(P <0.05),and the inhibition of leukocytes,granulocytes and platelets was significantly alleviated(P <0.05,P<0.05,P <0.05) compared with the control group.The myelosuppression induced by paclitaxel+platinum-based agents,pemetrexed+platinum-based agents was significantly alleviated(P <0.05,P <0.05,P <0.05,P <0.05) compared with the control group.Conclusion ABD Bioactives can alleviate chemotherapy induced myelosuppression in lung cancer patients,especially reduce the incidence of Myelosuppression of Ⅲ～Ⅳ,increase the levels of leukocytes,granulocytes and platelets,reduce the toxicity and side effects of platinum-based agents,paclitaxel,antimetabolite.更多还原